DISFRUTA ESTA NUEVA ETAPA EN TU VIDA

Complemento alimenticio de uso diario a base de:

  • Omega-3 EPA/DHA de ALTA CONCENTRACIÓN
  • Isoflavonas de soja
  • Calcio y Vitamina D3
Om3gafortSCC utiliza ácidos grasos poliinsaturados omega-3 EPA/DHA de ALTA CONCENTRACIÓN, EFICACIA, PUREZA y SEGURIDAD obtenidos con una tecnología ECOLÓGICA conocida como Supercritical Concentration (SCC).

Omegafort menopausia 40+, una combinación ganadora

COMPOSICIÓN

INFORMACIÓN NUTRICIONAL

Dosis diaria: 2 cápsulas. CDR referido a la dosis diaria.

2 cápsulas % CDR*
Ácidos grasos omega-3# 1040,4 mg **
EPA (ácido eicosapentaenoico) 795,6 mg **
DHA (ácido docosahexaenoico) 122,4 mg **
Otros omega-3 122,4 mg **
Otros ingredientes principales  **
Calcio 240 mg 30%
Extractos de soja Glycine max 100 mg **
Genisteína 20 mg
Total de isoflavonas 40 mg
Vitamina E 24 mg 200%
Vitamina D3 10 µg 200%
*Cantidades Diarias Recomendadas establecidas en la Directiva 2008/100/CE de 28 de octubre de 2008.
**Cantidades Diarias Recomendadas no establecidas.
#Cantidad mínima garantizada de ingrediente activo en mg.
Los porcentajes calculados sobre la cantidad mínima en mg pueden variar.

LISTA DE INGREDIENTES:

Aceite de pescado (mínimo: 65% de EPA [ácido eicosapentaenoico] y 10% de DHA [ácido docosahexaenoico] y otros omega-3), carbonato de calcio, gelatina, glicerina, espesante: lecitina de soja, triglicéridos de cadena media, emulsionante: monoesterato de glicerilo, extractos de soja (Glycine max) (isoflavonas, genisteína), vitamina E (acetato de D-alfa-tocoferilo), antioxidantes: extracto rico en tocoferoles, vitamina D3 (colecalciferol), colorantes (E 171 y E 129).

Mayor concentración, mayor eficacia

EPA
  1.  Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2009 Oct;206(2):535-9. Epub 2009 Apr 5.
  2. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators. Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40. Epub 2008 Jun 19.
  3. Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause. 2009 Mar-Apr;16(2):357-66.
  4. Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr. 2009 Feb;89(2):641-51. Epub 2008 Dec 30.
  5. Miyajima T, Tsujino T, Saito K, Yokoyama M. Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension. Hypertens Res. 2001 Sep;24(5):537-42.
ISOFLAVONAS DE SOJA
  1. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms – A systematic review. Mol Nutr Food Res. 2009 Sep;53(9):1084-97.
  2. Rudkowska I. Functional foods for cardiovascular disease in women. Menopause Int. 2008 Jun;14(2):63-9.
  3. Kurzer MS. Soy consumption for reduction of menopausal symptoms. Inflammopharmacology. 2008 Oct;16(5):227-9.
  4. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas. 2007 Nov 20;58(3):249-58. Epub 2007 Oct 29.
  5. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007 Apr;85(4):1148-56.
  6. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Tam S, Shu XO, Lau CP, Tse HF. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr. 2007 Oct;86(4):938-45.
  7. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Tam S, Shu XO, Lau CP, Tse HF. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr. 2007 Oct;86(4):938-45.
  8. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause. 2006 Sep-Oct;13(5):831-9.
CALCIO Y VITAMINA D
  1. Moschonis G, Katsaroli I, Lyritis GP, Manios Y. The effects of a 30-month dietary intervention on bone mineral density: the Postmenopausal Health Study. Br J Nutr. 2010 Jul;104(1):100-7. Epub 2010 Apr 7.
  2. Di Daniele N, Carbonelli MG, Candeloro N, Iacopino L, De Lorenzo A, Andreoli A. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial. Pharmacol Res. 2004 Dec;50(6):637-41.
  3. Gennari C. Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr. 2001 Apr;4(2B):547-59.